Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Insulin glargine in the treatment of type 1 and type 2 diabetes Barnett AHVasc Health Risk Manag 2006[]; 2 (1): 59-67Insulin glargine is an analogue of human insulin that is modified to provide a consistent level of plasma insulin over a long duration. Pharmacokinetic and pharmacodynamic studies show that a single injection of insulin glargine leads to a smooth 24-hour time-action profile with no undesirable pronounced peaks of activity. In clinical trials, this profile has been associated with at least equivalent, if not better, glycemic control than other traditional basal insulins and a significantly lower rate of overall and nocturnal hypoglycemia. The convenience of a once-daily injection, a lack of need for resuspension (insulin glargine is a clear solution when injected), and lower rates of hypoglycemia should translate into improvements in patient treatment satisfaction. This review appraises the evidence for the view that insulin glargine represents an advance in basal insulin therapy for both type 1 and type 2 diabetes patients.|Blood Glucose/drug effects[MESH]|Cardiovascular Diseases/etiology/prevention & control[MESH]|Delayed-Action Preparations[MESH]|Diabetes Mellitus, Type 1/blood/complications/*drug therapy[MESH]|Diabetes Mellitus, Type 2/blood/complications/*drug therapy[MESH]|Diabetic Angiopathies/etiology/prevention & control[MESH]|Drug Administration Schedule[MESH]|Glycated Hemoglobin/metabolism[MESH]|Humans[MESH]|Hypoglycemia/chemically induced[MESH]|Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use[MESH]|Injections, Subcutaneous[MESH]|Insulin Glargine[MESH]|Insulin, Long-Acting[MESH]|Insulin/administration & dosage/adverse effects/*analogs & derivatives/blood/therapeutic use[MESH]|Patient Compliance[MESH]|Patient Satisfaction[MESH]|Practice Guidelines as Topic[MESH]|Risk Factors[MESH]|Treatment Outcome[MESH] |
